InflaRx is no longer trying to be a hospital commercial company. After a January restructuring that cut about 30% of the workforce and ended active GOHIBIC selling in the United States, the Dutch-listed group is a cash-rebuilt clinical vehicle pointed at ANCA-associated vasculitis, a rare small-vessel disease that often scars the kidney. The oral C5a receptor blocker izicopan, formerly INF904, is now the lead. The intravenous anti-C5a antibody vilobelimab sits behind it as a Phase 3-ready option in the same biology. The investment debate is not whether complement matters in this disease. It is whether a vacated European franchise for the only marketed C5a receptor pill, avacopan sold as Tavneos, converts into a real InflaRx path before the new cash is spent on trials that still have not started.
The June CHMP recommendation to revoke Tavneos, later adopted by the European Commission in early August, is the event that re-rates the story. The revocation rests on good-clinical-practice failures in the ADVOCATE study, not on a finding that C5a receptor blockade is biologically empty. That distinction is load-bearing. InflaRx already ran two controlled Phase 2 vasculitis studies with vilobelimab and can point to Chinese Phase 3 work on a related cell-line antibody at Staidson. Management is now talking to the European regulator about both the antibody and the oral. A May registered offering priced at $2 a share brought in EUR 119 million net. Combined funds then stood at EUR 158 million. That recapitalization is why the equity trades as an option on a franchise rather than as a leftover from a failed hospital launch.
The strongest counterargument is that the company still has no product revenue, no started vasculitis Phase 2 for izicopan, and only open-label four-week dermatology data to support the oral's clinical activity. Hidradenitis and chronic hives are now partner-gated. The mid-year operating cash outflow of EUR 10 million looks cheap only because late-stage vilobelimab work and the hospital sales force are gone. Once a multi-arm renal program is actually enrolling, burn rises. Pre-funded warrants from the February 2025 raise marked a EUR 7 million fair-value hit in the first half, a reminder that the capital structure still has a live derivative overlay. The market can be right about the European vacuum and still be early on InflaRx as the occupant.
Four variables decide the next year. First is whether European and United States regulators accept a vasculitis path that uses existing vilobelimab data or insist on a long new oral program. Second is whether izicopan actually opens a Phase 2 vasculitis study around the turn of the year. Third is whether a partner funds the hidradenitis and hives work that management no longer intends to carry alone. Fourth is whether cash use stays near the current lean rate or doubles as trials start. The October Capital Markets Day is the first dated forum where those four items either tighten or stay vague. A reader who leaves that session still unable to name a protocol family or a first-patient window should treat the equity as a cash option with a story attached, not as a rare-disease compounder in waiting.